10.1158/0008-5472.CAN-15-3376 13
Regulate tight junction proteins, maintaining barrier integrity
PMID 21296191
(All committee members underwent the same ethics review and vetting process required of all FDA advisory committee members, Emily Hilliard, a spokesperson for the Department of Health and Human Services, told me in an email.) The decision is only a recommendation, and the FDA would still need to sign off on an actual rule change
Tel : 609-228-6898 Technical Support : [email protected] Purity & Documentation Data Sheet (274 KB) SDS (394 KB) English - EN (394 KB) Franais - FR (394 KB) Deutsch - DE (394 KB) Norwegian - NO (394 KB) Espaol - ES (394 KB) Swedish - SV (394 KB) Italian - IT (394 KB) Korean - KR (394 KB) Portuguese - PT (394 KB) Handling Instructions (2659 KB) References [1]
In some cases, vacuolar peptidases may cleave the glutamate and glycine of the original glutathione molecule, leaving the cysteinyl conjugate (cysteine-X) which may need further processing in Phase III reactions, such as incorporation into cell wall material